Epidermal growth factor (EGF) receptor (EGFR), a member of the EGF superfamily of receptor tyrosine kinases, is a critical regulator of cell growth and an important target for single agent and combination anticancer therapeutics. To further investigate the dynamics of ligand-induced EGFR processing and regulation noninvasively, we developed a chimeric EGFRfirefly luciferase (FLuc) fusion reporter to directly monitor processing of EGFR in real-time. In a stable HeLa cell line expressing the reporter at physiologically relevant levels, bioluminescence imaging continuously monitored reporter dynamics, correlating with the ligand-induced response of endogenous EGFR as determined by Western blot, subcellular localization of an EGFR-green fluorescent protein (GFP) fusion protein, and validated pharmacologic responses. The signaling competency of the reporter was confirmed by gene rescue experiments in EGFR-null cells. Bioluminescence analysis further showed that proteasome inhibition with bortezomib or MG132 attenuated overall ligand-induced degradation of EGFR. In cells expressing EGFR-GFP, pretreatment with proteasome inhibitors trapped essentially all of the receptor at the cell membrane both before and after ligandinduced activation with EGF. Furthermore, proteasome inhibition enhanced receptor ubiquitination in both the basal and ligand-activated states as well as delayed the processing of ligand-activated phosphorylation of the receptor, kinetically correlating with attenuated receptor degradation. These observations point to a potential mechanism for the synergistic therapeutic effects of combination EGFR-and proteasome-targeted therapies. [Cancer Res 2009;69(3):976-83] 
Introduction
Growth factor receptor tyrosine kinases (RTK) have been extensively studied for decades and continue to be a focus of investigation and drug targeting because of their central roles in development, proliferation, motility, survival, apoptosis, and differentiation. The epidermal growth factor (EGF) receptor (EGFR), also known as ErbB1, is one of four members of the ErbB family of RTKs, and is activated by a number of ligands, including EGF. Binding of EGF to EGFR activates the tyrosine kinase activity of the receptor, resulting in autophosphorylation of five tyrosine residues in the carboxy-terminal domain (1) . The activated receptor initiates several downstream signaling cascades, notably the Ras-mitogen-activated protein kinase (MAPK) pathway; activation of Ras GTPase is the major signaling event initiated by EGFR (2) .
Proteins in this pathway are also involved in receptor-mediated endocytosis, another major processing pathway triggered by ligand binding. After autophosphorylation, EGFR is ubiquitinated and targeted for internalization. Through use of differential antibody affinity, it had been suggested that EGFR was exclusively monoubiquitinated. However, mass spectrometric analysis showed that over half of all EGFR-associated ubiquitin is in the form of polyubiquitin chains rather than monoubiquitin; chains linked via lysine 63 represent the most prevalent form of polyubiquitination (3, 4) . Although the significance and exact mechanisms of ubiquitination remain unresolved, the ubiquitin-dependent internalization of EGFR represents an example of the general contribution of ubiquitin to degradation of receptors.
Ubiquitination also is thought to act as a signal for postendocytotic processing, leading EGFR through the endosomal pathway to either subsequent degradation in the lysosome or recycling back to the plasma membrane (5) (6) (7) (8) , where receptor functionality is maintained (9) . This interplay between EGFR activation, degradation, and recycling form complex signaling layers interconnected by regulators with time and context restrictions (e.g., ligand type, cell density) that dictate EGFRdependent responses (proliferation, survival, adhesion, differentiation, and migration; refs. 2, 10, 11) . Perturbation of this interplay results in disease states, notably many types of cancer (12) . For example, overexpression of EGFR is characteristic of 40% of gliomas and is especially correlated with poor prognosis in breast carcinoma, colon cancer, and non-small cell lung cancer (NSCLC; refs. [9] [10] [11] [12] . New drugs, such as the tyrosine kinase inhibitors (TKI), are at the forefront of the search for effective treatments for these cancers, especially NSCLC; both monoclonal antibodies and quinazoline-based small molecules targeting EGFR tyrosine kinase activity have been developed (13) (14) (15) (16) .
Given that the first generation of small molecule TKIs targeting EGFR seem to be effective in only a small subset of cancer patients (17) (18) (19) (20) , further exploration of the regulation of EGFR is warranted to better understand detailed mechanisms of receptor internalization and signal transduction. This may provide potential new targets to interfere with the increased signaling that is a hallmark of EGFR overexpression and tumorigenesis, and a better understanding of the kinetics of receptor activation would provide insight into potential ways to interfere with the altered equilibrium state characteristic of cancer. In this regard, a previously designed EGFR-based model has been used to follow glioma cell proliferation and burden in vivo (21) . This model involved whole animal imaging of nude mice into which glioma cells expressing either a EGFR-green fluorescent protein (GFP)-Renilla luciferase fusion (EGFR-GFP-RLuc) or mutant EGFRvIII-GFP-RLuc to monitor EGFR content and a constitutive firefly luciferase-red fluorescent protein fusion (FLuc-DsRed2) to monitor tumor cell mass were implanted into the brain. Although the authors showed increased EGFR expression and glioma growth over time both in vitro and in vivo, the bursting photonic activity profile of the Renilla luciferase reporter did not allow examination of the early kinetics of intracellular processing and degradation of EGFR. We herein present a firefly luciferase-based EGFR fusion reporter strategy for real-time imaging of ligand-induced processing and regulation of EGFR in live cells. The chimera reporter was used to examine the effect of proteasome inhibition on receptor processing.
Materials and Methods
Plasmids. pCMV-EGFR-GFP was a gift from Alexander Sorkin (University of Colorado). To generate pCMV-EGFR-FLuc, firefly luciferase sequences (FLuc) were PCR-amplified from the pGL-3 control plasmid (Promega) along with a SacII site and a sequence encoding for a 12 amino acid linker (PRSGGSSSGGLA) upstream of FLuc and an XbaI site downstream of FLuc, and ligated into a TOPO TA vector (Invitrogen). After excision of GFP from pCMV-EGFR-GFP with SacII and XbaI, the FLuc PCR product was excised from the TOPO TA vector with SacII and XbaI and ligated into the pCMV-EGFR-containing backbone. pCMV-FLuc was similarly constructed and used as a control plasmid, along with pcDNA3 (Promega). pMyc-ubiquitin was a gift from Helen Piwnica-Worms (Washington University, St. Louis, MO).
Cell lines, transfections, and reagents. HeLa cells were cultured at 37jC under 5% CO 2 in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% glutamine, and 0.1% penicillin/streptomycin solution. Cells were grown on glass coverslips for transient transfections (0.5 mg total DNA/100,000 cells) using Fugene 6 (Roche Applied Science) as recommended. ) were created by selection in 1 or 0.5 mg/mL G418, respectively. NR6 cells were a gift from Harvey Herschman (University of California, Los Angeles, CA) and were cultured at 37jC under 5% CO 2 in low-glucose/high-bicarbonate DMEM supplemented with 10% heat-inactivated FBS, 1% glutamine, and 0.1% penicillin/ streptomycin solution. Cycloheximide, tyrphostin AG1478, MG132, and wortmannin were purchased from Sigma. Bortezomib was a gift from Millennium Pharmaceuticals.
Fluorescence microscopy. 4 ¶,6-diamidino-2-phenylindole (DAPI) and GFP expression were detected using an inverted Zeiss Axiovert 200 inverted confocal microscope coupled to a Zeiss LSM 5 PASCAL Vario Two UGB system fitted with a 405 nm diode laser and a 488 nm Ar laser.
Bioluminescence imaging in cell culture. For experimental consistency, cells were seeded and used at subconfluent levels (f70% confluency, except when otherwise indicated) in black 24-or 96-well plates (Corning). Immediately before imaging, cells were washed once with MEBSS and incubated for 30 to 60 min with 150 Ag/mL D-luciferin in MEBSS supplemented with 1% heat-inactivated FBS. EGF (Cell Signaling Technology) was added to a final concentration of 100 ng/mL and bioluminescence imaging was performed using the IVIS 100 (Caliper Life Sciences) imaging system (various exposure times; binning 8; no filter; f/stop 1; FOV 15 cm). All cellular studies were performed in quadruplicate wells with at least two different culture preparations.
Statistics and curve fitting. Data are presented as mean photon flux of treated wells as a percentage of photon flux of untreated wells plotted as a function of time after treatment F SE of quadruplicate wells. Curve fitting was performed using the sigmoidal concentration-response nonlinear regression [y = Min + (Max À Min)/(1 + 10^(LogEC50 À x)), where x = log concentration] in GraphPad Prism 4 (GraphPad Software).
Western blots and immunoprecipitation. EGFR was detected in whole cell lysates derived from HeLa or HeLa EGFR-FLuc cells using rabbit anti-EGFR antibody at 1:1,000 (Cell Signaling Technology). Phospho-MAP/ERK kinase was detected in whole cell lysates derived from NR6 cells using rabbit antiphospho-MEK antibody at 1:400 (Santa Cruz Biotechnology). Blots were probed with anti-rabbit secondary antibodies at 1:1,000 (Amersham Biosciences), developed with the enhanced chemiluminescence Western Blotting reagent (Amersham Biosciences), and imaged using the IVIS 100 imaging system (exposure time, 1 min; binning, 4; no filter; f/stop, 1; FOV, 15 cm). Blots were also stripped and reprobed with anti-actin antibody at 1:400 (Sigma). For immunoprecipitation, cells were washed with ice-cold PBS and lysed on ice in lysis buffer [50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 5% glycerol (w/v), 1% Triton X-100, 1 mmol/L EDTA, 1 mmol/L EGTA, 10 mmol/L NaF, 30 mmol/L glycerol phosphate, 1 mmol/L Na3VO4, and 1 AL/10 6 cells proteinase inhibitor cocktail (Sigma)]. Lysates were shaken for 20 min at 4jC and then centrifuged at 4jC for 15 min at 14,000 g. Supernatant equivalent to 1 mg of protein was adjusted to 1 mL with lysis buffer, mixed with 2.5 Ag anti-EGFR antibody (Clone 528; Calbiochem) or 40 AL anti-FLAG antibody slurry (M2 Affinity Gel; Sigma), and incubated for 2 to 3 h at 4jC. The complexes were precipitated overnight at 4jC with 30 AL protein A agarose conjugate (Sigma). Complexes were washed three times with lysis buffer before being loaded for fractionation and immunoblotting. Immunoblotting was carried out using P4D1 rabbit anti-ubiquitin antibody at 1:1,000 (Santa Cruz) or mouse anti-Myc antibody at 1:1,000 (Sigma). Blots were probed with anti-rabbit or anti-mouse secondary antibodies at 1:1,000 (Amersham Biosciences) and developed and imaged as above.
Results
Characterization of an EGFR-FLuc reporter construct. To monitor ligand-induced processing and degradation of EGFR, we engineered a new fusion reporter construct, pCMV-EGFR-FLuc, in which firefly luciferase was fused to the COOH terminus of EGFR driven by a cytomegalovirus (CMV) promoter. A 12 amino acid glycine-serine-rich linker between the receptor and the luciferase allowed flexibility of the protein domains with the intent to minimize steric constraints on receptor processing ( To accurately image changes in receptor levels in real-time, time course imaging of HeLa EGFR-FLuc cells was performed with a cooled CCD imaging system (IVIS) at 37jC before and upon addition of EGF (100 ng/mL). To account for nonspecific changes in photon output from the luciferin-luciferase reaction over time as Dluciferin was consumed, the photon flux from the ligand-treated cells was divided by the photon flux from cells treated with vehicle. This ratio was then normalized so that the initial value was 100%, and data presented as a percent of the photon flux of untreated cells. The response of the EGFR-FLuc reporter to treatment with EGF (100 ng/mL) shows a highly reproducible initial decrease in photon flux, which correlated with the expected time course of receptor internalization and degradation over the first 30 to 45 min (Fig. 1B) , followed by a signal rebound. We hypothesized that the rebound phase was a period of net reporter synthesis driven by the constitutive CMV promoter and posttranslational stabilization, exceeding the diminishing dynamics of the degradation events after 30 to 45 min, a phenomenon we have observed with other kinetically regulated bioluminescent fusion reporters (24, 25) .
Expanding the range of ligand concentrations used to activate subconfluent HeLa EGFR-FLuc cells showed a concentration-dependent decrease in photon flux during the first 30 min (Fig. 1C) . Normalizing to the percentage of maximum degradation at 30 min, titration curve fitting showed an EC 50 of 10.4 ng/mL (R 2 = 0.9996; Fig. 1D ) for the EGFR-FLuc reporter degradation. This compared favorably to the known EC 50 of 16 ng/mL for EGF-induced EGFR dimerization documented in the literature (26) . Consequently, a saturating concentration of EGF (100 ng/mL) was used in all subsequent experiments.
To confirm the signaling competency of the EGFR-FLuc fusion reporter, gene rescue experiments were carried out in NR6 fibroblast cells, an EGFR-null cell line (27) . In subconfluent NR6 cells transiently transfected with EGFR-FLuc, exposure to EGF confirmed bioluminescence profiles of degradation and rebound kinetics of reporter photon flux similar to those observed in HeLa EGFR-FLuc cells (data not shown). The NR6 line was then used to examine the capacity of the EGFR-FLuc reporter to activate downstream targets of EGFR signaling, such as members of the MAPK pathway. Using an anti-phospho-MEK antibody, Western blots of whole cell lysates from transfected NR6 cells directly showed activation of the MAPK pathway by EGFR-FLuc, but not control vector ( Fig. 2A) , confirming the EGF-induced signaling competency of the expressed chimera reporter.
Further analysis of pharmacologic effects on EGFR-FLuc processing was also performed. Treatment of HeLa EGFR-FLuc cells with tyrphostin AG1478 (10 Amol/L), a specific inhibitor of EGFR kinase activity (28) , indicated that ligand-induced receptor degradation was dependent on kinase activity (Fig. 2B) . Again, blockade of the rebound phase by kinase inhibition was considered to be a nonspecific effect on CMV promoter-driven synthesis and posttranscriptional processing of the reporter system. Ubiquitinated EGFR is recruited for sorting to multivesicular endosomes (MVE) by components of the endosomal sorting complex required for transport-I, specifically, hepatocyte growth factor-regulated tyrosine kinase substrate bound to phosphatidylinositol-3-phosphate (29, 30) (Fig. 2C) .
EGF (100 ng/mL) was then used to test the effect of cell contact-dependent modulation of EGFR internalization and signaling (31, 32) on the magnitude of EGFR-FLuc degradation dynamics. As expected, the maximum dynamic range of degradation was observed with sparsely plated HeLa EGFR-FLuc cells, whereas fully confluent HeLa EGFR-FLuc cells showed no degradation of EGFR-FLuc in response to EGF (Fig. 3A) . The effect of CMV-driven production of the reporter remained evident, however, as a signal ''rebound.'' Note comparable kinetics of rebound in the fully confluent and subconfluent cells, but altered initiation of rebound in sparse cells, an effect partially observed in Fig. 1C . For the purposes of this study, we therefore concluded that the rapid degradation phase induced by ligand binding represented the most physiologically relevant signals from the EGFR-FLuc reporter.
The bioluminescence signal was also analyzed in the presence of the translation inhibitor cycloheximide to confirm that the observed ligand-induced decrease in signal was a function of the EGFR component of the reporter. In HeLa EGFR-FLuc cells, pretreatment with cycloheximide for 1 h did not effect the first 45 min of degradation after EGF treatment but completely abrogated the rebound of bioluminescent signal over the subsequent 75 min (Fig. 3B) . By contrast, in HeLa cells stably expressing control pCMV-FLuc (HeLa FLuc ), pretreatment with cycloheximide for 1 h followed by addition of EGF showed no dynamic minimum. Thus, upon stimulation of HeLa FLuc cells with EGF, the lack of response in the presence of cycloheximide indicated that there was essentially no effect of EGF on FLuc degradation, whereas the lack of response in the presence of vehicle (DMSO) showed that there was no significant effect of EGF on FLuc protein synthesis. Similar results were obtained after pretreating HeLa
FLuc and HeLa EGFR-FLuc cells with the transcription inhibitor actinomycin-D (Fig. 3C) . Overall, these experiments were again consistent with a biphasic response of the EGFR-FLuc reporter consisting of an initial processing/ degradation phase and a subsequent rebound phase, the latter being a result of CMV promoter-driven EGFR-FLuc synthesis. Although both cycloheximide and actinomycin-D blocked the rebound phase of signal increase, neither had an effect on the physiologically-relevant posttranslational processing and early degradation phase of the reporter.
Fluorescence microscopy was used to characterize an identical construct containing enhanced GFP instead of FLuc fused to EGFR. After transient transfection into HeLa cells, the fluorescent reporter protein showed correct localization to the plasma membrane under basal conditions (Fig. 4A) . In response to treatment with EGF, a submembranous punctuate pattern developed along with loss of fluorescence intensity over the ensuing 20 to 60 min, consistent with ligand-induced endocytosis, relocalization to internal vesicles, and degradation of EGFR-GFP. As this GFP isoform requires several hours to mature fully (33), newly translated fluorescent fusion protein failed to be visualized over the time frame of these experiments. As a result, the kinetic pattern of photonic output of the GFP-based reporter system was analogous to the bioluminescent system in the presence of cycloheximide.
To show that EGFR-FLuc reporter levels were an accurate reflection of the response of endogenous EGFR to EGF over time, we compared the dynamic response of bioluminescence of HeLa EGFR-FLuc cells in the presence of cycloheximide (Fig. 4B) to Western blot analysis of whole cell lysates of parental HeLa cells (Fig. 4C) , each obtained after treatment with EGF (100 ng/mL). Semiquantitative densitometric analysis of Western blots (anti-EGFR) showed excellent correlation between endogenous EGFR and EGFR-FLuc chimera protein levels (R 2 = 0.97; Fig. 4D ). Similarly, in HeLa cells transiently transfected with EGFR-FLuc-FLAG, excellent correlation was observed between EGFR-FLuc bioluminescence output and FLAG-tagged chimera protein levels (R 2 = 0.89; data not shown).
Effect of proteasome inhibitors on EGFR processing. Partial blockade of EGFR-FLuc degradation was also achieved pharmacologically by pretreatment of HeLa EGFR-FLuc cells with two proteasome inhibitors. At concentrations of bortezomib or MG132 at which proteasomal activity was nearly completely inhibited (34) , the level of ligand-induced degradation decreased f50% (Fig. 5A  and B) . In HeLa EGFR-FLuc cells pretreated with cycloheximide (to directly remove the contribution of signal rebound), the change in receptor degradation as a result of proteasome inhibition was shown to be concentration dependent (Fig. 5C ). The EC 50 was calculated to be 0.063 Amol/L (data not shown; R 2 = 0.962), identical to the apparent EC 50 of bortezomib-induced inhibition of the proteasome (34) .
To test the hypothesis that proteasome inhibition modulates the EGF-induced subcellular relocalization of EGFR, HeLa cells were transiently transfected with EGFR-GFP and pretreated with either bortezomib or MG132. At various time points after addition of EGF, cells were fixed and images obtained by confocal microscopy (Fig.  5D ). Untreated cells, maintained in a 1% serum solution for the duration of the experiment, showed a small amount of internal receptor, but the vast majority of EGFR was localized to the plasma membrane (Fig. 5D, first column) . As expected, treatment with EGF alone resulted in essentially complete internalization of the protein by 30 min (Fig. 5D, second column) . In contrast, pretreatment with bortezomib or MG132 alone for 1 hour resulted in trapping of essentially all of the protein at the plasma membrane. Remarkably, there was a distinct absence of cytosolic receptor and punctate endosomal compartments after 1 hour of treatment with proteasome inhibitor (Fig. 5D, fourth column) . Stimulation of proteasome-inhibited cells with EGF resulted in modest internalization of EGFR, but a majority of the protein remained at the cell membrane, even after 60 to 100 min (Fig. 5D, third column) .
To test the hypothesis that proteasome inhibition affects the phosphorylation status of EGFR, HeLa EGFR-FLuc cells were pretreated with either bortezomib or vehicle and then activated with EGF. A Western blot of whole cell lysates from various postactivation time points using an anti-phospho-EGFR antibody indicated that EGFR was still phosphorylated in the presence of bortezomib (Fig. 6A) . However, densitometry analysis of both the endogenous EGFR as well as the EGFR-FLuc reporter indicated that bortezomib significantly delayed degradation of phosphorylated species of both proteins approximately equally (Fig. 6B) .
To determine if proteasome inhibition affected the ubiquitination of EGFR, HeLa EGFR-FLuc cells as well as HeLa cells transiently transfected with both EGFR-GFP and Myc-tagged ubiquitin, were pretreated with MG132 or vehicle and then activated with EGF. Western blot analysis of cell lysates for ubiquitinated EGFR-FLuc (Fig. 6C, left) or EGFR-GFP (Fig. 6C, right) indicated that EGFR was rapidly ubiquitinated post-EGF activation, and furthermore, MG132 pretreatment enhanced the ubiquitination state post-EGF activation (Fig. 6C, compare lanes 2 and 4 in both panels) . The smeared band visible only after activation with EGF is consistent with EGFR protein that was both phosphorylated and ubiquitinated at multiple sites. Notably, treatment with MG132 alone increased the basal level of ubiquitination even in the absence of EGF (Fig.  6C, lane 3 in both panels) . Together, the confocal microscopy and Western blot data indicated that treatment with proteasome inhibitors alone changed not only the localization and compartmentation of EGFR, but also its basal ubiquitination state, which 
Discussion
The degradation pathway of EGFR, long used as a model of RTK processing, is highly regulated in both subcellular localization and kinetics by numerous extracellular and intracellular processes. Even as EGFR continues to be a highly desirable therapeutic target, many aspects of receptor regulation remain poorly defined. Understanding the dynamics of this receptor will be crucial not only in evaluating new drugs in cellular and animal models but also in identifying potential new targets. Thus, we have developed a reporter (EGFR-FLuc) that allows monitoring of EGFR processing and degradation in intact cells in real-time, thereby providing a transcriptionally uncoupled readout of the degradation of the receptor.
Overall, EGFR-FLuc bioluminescence indicated that the reporter protein provided an accurate readout of the total population of receptor in living cells. Temporal profiles of the effects of various pharmacologic agents were made possible by real-time imaging of HeLa EGFR-FLuc cells within minutes after stimulation, and dynamic monitoring was easily extended to different experimental setups, such as changes in cell lines or ligand concentration. In comparison to more conventional transcriptional assays, real-time imaging of photon output from the reporter population allowed for essentially immediate phenotypic readout reflecting key posttranslational modifications in receptor processing, such as ubiquitination (Figs. 5 and 6 ). Importantly, because bioluminescence imaging allowed for readout of the total receptor population, whole cell lysates were used in Western blots to correlate with the bioluminescence data. The large smear representing the multiphosphorylated and polyubiquitinated EGFR visible on the Western blots provided further evidence for the complexity of the status of the receptor post ligand engagement. Many typical biochemical protocols used to study EGFR involve immunoprecipitation followed by immunoblotting, thereby selecting for subpopulations of receptor; results from such protocols may be further confounded by differential antibody affinity for these subpopulations.
The new observation from this study was that pretreatment of HeLa EGFR-FLuc cells with the pharmacologically relevant concentrations of proteasome inhibitors bortezomib or MG132 significantly decreased ligand-induced degradation of EGFR by f50%, but enhanced both basal and ligand-induced ubiquitination of the receptor (Figs. 5 and 6 ). The data were consistent with a major role for the proteasome in the processing and degradation of EGFR. It remains to be determined if the contribution of the proteasome was direct, where a certain subpopulation of receptor was targeted to the proteasome for degradation, or if the contribution of the proteasome was indirect. An indirect mechanism would suggest that a proteasomally regulated protein was a key modulator of one or more of the early steps of the EGFR degradation pathway. Our data further indicated that correct subcellular localization was a requirement for proper processing of the receptor and it was strikingly altered in the presence of proteasome inhibition (Fig. 5D) . The decreased degradation in the presence of bortezomib or MG132 could therefore be attributed to trapping of EGFR at the cell membrane, thereby preventing it from proceeding into the endosomal pathway for appropriate processing/degradation. Bortezomib (Velcade), an approved therapy for multiple myeloma in both the United States and Europe, is now under investigation for efficacy in the treatment of solid tumors, including non-small cell lung, breast, pancreatic, and colon cancers (35) , all cancers that potentially overexpress EGFR (9) (10) (11) (12) . Although the mechanism of the antitumor activity of bortezomib remains poorly understood, possibly significant molecular sequelae include inhibition of nuclear factor-nB activation, induction of cell cycle arrest, and effects on Bax and Bcl-2 leading to induction of apoptosis (36) (37) (38) (39) . Enhanced apoptosis was more recently observed when bortezomib was combined with both small molecule TKIs and monoclonal antibodies targeted against EGFR (35) .
We propose several possible mechanisms for the promising effects of bortezomib in combination with EGFR inhibitors in the treatment of solid tumors, based on our observation that proteasome inhibition decreases degradation and significantly alters subcellular localization of EGFR, specifically by trapping receptor at the plasma membrane in a ubiquitination-dependent manner. EGFRs at the plasma membrane therefore remain accessible to inhibition by monoclonal antibodies targeting extracellular motifs of the receptor surface. Furthermore, small molecule TKIs may also have increased ability to access the ATPbinding site of the tyrosine kinase domain of EGFR localized to the plasma membrane, as accessibility for drugs may be compromised when the receptor is internalized and localized within the MVE.
Alternatively, it is possible that phospho-and ubiquitinationdependent allosteric conformations of the receptor or kinase domains specifically induced by proteasome inhibitors favor binding or increase the affinity of TKIs for EGFR. Fundamentally, the basal state of the cell is significantly altered after proteasome inhibition, given the changes in ubiquitination and subcellular localization that are visible after proteasome inhibition, even in the absence of ligand. This proteasome-inhibited cell can therefore also be expected to respond differently to receptor-targeted therapy, which may enhance the efficacy of drug combinations targeting EGFR. These models also provide implications for targeted therapies against a multitude of cell surface receptors, which may be similarly affected by proteasome inhibition.
Considerable effort is under way to develop effective modulators of EGFR for treatment of various cancers; no fewer than eight drugs targeting the protein have been approved or are in clinical trials, with modest benefits thus far. We envision that EGFR-FLuc could be used in cellulo for screening of compounds that would modulate the deleterious effects of enhanced stimulation of downstream signaling pathways, as well as in vivo for further testing of lead compounds, including combination therapy with proteasome inhibitors such as bortezomib. The effects of any particular agent or gene on EGFR could be monitored in real-time on a variety of genetic backgrounds. In combination with readouts of downstream pathway activity, this reporter has the promise to provide insight into the well-studied yet still enigmatic processing of EGFR that is central to both normal physiology and many forms of malignancy.
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